Randomized Clinical Trial Results Confirm PleuraFlow Reduces Take Back for Bleeding in Cardiac Surgery Patients

Reduction in chest tube clogging and take back for bleeding shown in randomized prospective clinical trial with PleuraFlow ACT System IRVINE, CA —March 30, 2021 ClearFlow, Inc., a medical device company based in Irvine, California, has announced positive clinical trial results published in the peer-reviewed Journal of Cardiothoracic Surgery. The findings are reported by cardiac surgeons at the Montreal Heart Institute, in Montreal, Quebec, Canada in the article, “Active clearance vs conventional management of chest tubes after cardiac surgery: a randomized controlled study.” The randomized prospective trial evaluated the use of the PleuraFlow® Active Clearance Technology® (ACT®) System in the effective reduction of retained blood complications in heart surgery patients